菜单
CRO Services

Drug Development Expertise Empowering Research Services for Biologics

In Vivo Pharmacology Services


Science-Driven Solutions via Multi-Species Platforms

Our multi-species in vivo pharmacology services provide science-driven solutions for preclinical studies, including pharmacokinetic (PK) and pharmacodynamic (PD) evaluations, efficacy models, toxicology studies, and immunohistology.

 

With a proven track record of over 800 projects, we support a wide variety of therapeutic modalities, such as monoclonal, bispecific, and multispecific antibodies, antibody-drug conjugates (ADCs), fusion proteins, and CAR-T therapies. Our comprehensive platform covers diverse therapeutic areas such as oncology, autoimmune diseases, and metabolic disorders, ensuring a seamless transition from preclinical research to clinical trials, IND filings, and beyond.

 

Key Features of Our In Vivo Pharmacology Services:

  • Pharmacokinetics and Pharmacodynamics (PK/PD), Anti-Drug Antibody (ADA) & Exploratory Toxicity Study: Assess drug behavior, immune response, and preliminary safety profiles
  • Efficacy Studies: Conduct across a range of disease and tumor models
  • In Vivo Imaging & Biodistribution: Real-time live image tracking of therapeutic antibody candidates
  • Immunohistochemistry (IHC): Perform precise tissue diagnosis and validation of biomarkers

Mouse on plate for in vivo pharmacology services, including PKPD studies, toxicology assessments, efficacy testing and immunohistology to accelerate your drug development process.

Frequently Asked Questions for In Vivo Pharmacology

Q: What types of animal models are most commonly used in in vivo pharmacology?

A: Rodents (mice and rats) are most frequently used for the lead screening in PK and efficacy studies due to low cost, potentiality of humanization, gene transfection, and advantages in the fast development of various model diseases, while non-human primates (NHPs) are used for GLP and non-GLP PK/PD/Tox studies due to the high degree of genetic similarity to human in pharmacokinetics (PK) and toxicology.

Q: How do in vivo PK/PD studies support selection for preclinical trials?

A: By measuring blood drug concentration and metabolism like PK, alongside with biological effects like PD and efficacy and drug related toxicity, in vivo studies help to determine the minimum effective dose (MED) and maximum tolerated dose (MTD) to optimized the therapeutic window and first-in-human dosing.

Q: What role does immunophenotyping play in in vivo studies?

A: Immunophenotyping characterizes immune cell subsets in treated animals, providing insights into immunomodulatory effects and therapeutic mechanisms of action (MOA).

Q: How do biologics drug discovery integrate with in vivo pharmacology?

A: Biologics discovery services span molecular design, antibody discovery platform selection, lead optimization, antibody & protein production, protein characterization, in vitro assays, and in vivo pharmacology. At WuXi Biologics, our streamlined workflows ensure zero lead time from protein production to animal reservation and NHP or murine PK/PD/Tox/efficacy studies within the same department and the same core group, accelerating your path to preclinical success.

Q: What are the advantages of using WuXi Biologics CRO Services for in vivo studies?

A: We offer science-driven in vivo pharmacology services via multiple species, backed by extensive drug development expertise. This allows rapid iteration, rational study design, and customized solutions for diverse modalities like bispecific t cell engagers (TCEs) and antibody-drug conjugates (ADCs), and expert interpretation and troubleshooting.

Q: How does mechanism of action (MOA) analysis guide drug development?

A: MOA studies reveal how a drug interacts with its target at the molecular and cellular levels. Understanding MOA ensures rational drug design, in vitro assays, and animal model development, improved dosing strategies, and reduced risk in clinical trials.

Q: What role does immunohistochemistry (IHC) play in pharmacology studies?

A: IHC enables visualization of drug targets, biomarkers, and tissue distribution as well as diagnosis of drug related toxicity (i.e. infiltration of inflammatory cells). It helps researchers confirm target engagement, validate mechanisms of action (MOA), and correlate drug exposure and toxicity with therapeutic outcomes.

Q: How do pharmacokinetics (PK) and pharmacodynamics (PD) differ in drug discovery and development?

A: Pharmacokinetics (PK) describes how the body absorbs, distributes, metabolizes, and excretes a drug, while pharmacodynamics (PD) explains the biological effects and mechanisms of action (MOA). Together, PK/PD studies provide a complete understanding of drug behavior and therapeutic potential.

Your Project. Our Expertise.